Cohance Lifesciences Limited vs Dr. Reddy's Laboratories Limited
Last updated: 27 October 2026
MoneyDock presents a detailed comparison between two prominent players in the Indian pharmaceutical sector: Cohance Lifesciences Limited (COHANCE.NS) and Dr. Reddy's Laboratories Limited (DRREDDY.NS). While Cohance Lifesciences operates in a specialized segment, likely in contract development and manufacturing or active pharmaceutical ingredients, Dr. Reddy's is a globally recognized integrated pharmaceutical company with a wide portfolio of generics, branded formulations, and biosimilars. This comparison aims to provide investors with a clear perspective on their performance metrics, allowing for informed investment decisions based on their financial health and market standing.
Key Financial Metrics Comparison
| Metric | Cohance Lifesciences Limited | Dr. Reddy's Laboratories Limited |
|---|---|---|
| Current Price | ₹479.25 | ₹1310.00 |
| 52-Week High | ₹539.85 | ₹1374.10 |
| 52-Week Low | ₹279.90 | ₹1135.60 |
| 1-Year Return | -10.99% | 2.49% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When assessing these two pharmaceutical entities, several key aspects emerge from the available data. On valuation, both companies currently have a 'N/A' for Trailing P/E and Market Cap, which limits a direct valuation comparison based on these common metrics. However, their current stock prices and 52-week ranges offer some insights. Dr. Reddy's, with a current price of ₹1310.00, is significantly higher than Cohance Lifesciences at ₹479.25, indicating a potentially larger enterprise or a higher perceived value per share, although this needs to be contextualized with market capitalization.
In terms of returns, Dr. Reddy's Laboratories clearly outperforms Cohance Lifesciences over the past year. Dr. Reddy's posted a positive 1-Year Return of 2.49%, demonstrating a modest gain for its shareholders. In contrast, Cohance Lifesciences recorded a negative 1-Year Return of -10.99%, indicating a decline in stock value over the same period. This suggests that Dr. Reddy's has offered better capital preservation and growth over the last year compared to Cohance Lifesciences.
Regarding stability, the 52-week price ranges provide a glimpse into the volatility of each stock. Dr. Reddy's has a 52-week low of ₹1135.60 and a high of ₹1374.10, showing a relatively tighter range compared to its current price. Cohance Lifesciences, with a 52-week low of ₹279.90 and a high of ₹539.85, exhibits a much wider percentage swing relative to its current price. This wider range for Cohance could imply higher volatility or a more speculative nature, while Dr. Reddy's appears to have a more stable price trajectory within its 52-week window. The fact that Dr. Reddy's is currently trading closer to its 52-week high (₹1310.00 vs ₹1374.10) compared to Cohance Lifesciences (₹479.25 vs ₹539.85, but also significantly above its low of ₹279.90) further indicates differing market sentiments.
MoneyDock Verdict
For Aggressive Investors: Cohance Lifesciences, despite its negative one-year return, shows a wider 52-week price range, which could appeal to aggressive investors looking for higher volatility and potential for significant upward swings if market sentiment improves or specific company catalysts emerge. The lower current price also presents a potentially lower entry point for speculative growth.
For Conservative Investors: Dr. Reddy's Laboratories appears to be the more suitable choice for conservative investors. Its positive one-year return, albeit modest, and relatively tighter 52-week price range suggest greater stability and less risk compared to Cohance Lifesciences. As an established player, it offers a more predictable investment profile.
For Long-Term SIP Investors: Dr. Reddy's Laboratories would generally be favored for long-term Systematic Investment Plan (SIP) investors. Its demonstrated positive return over the year and presumed larger, more diversified business operations suggest a more robust foundation for consistent long-term growth. While Cohance could offer higher returns if it turns around, its current negative return and lack of P/E or Market Cap data introduce more uncertainty for a steady, long-term accumulation strategy.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.